ArQule (NASDAQ:ARQL) was upgraded by research analysts at Needham & Company LLC from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, Marketbeat reports.

A number of other research analysts have also recently issued reports on ARQL. Zacks Investment Research raised ArQule from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research note on Thursday, September 28th. ValuEngine raised ArQule from a “strong sell” rating to a “sell” rating in a research note on Friday, November 17th.

Shares of ArQule (NASDAQ:ARQL) traded up $0.01 during trading hours on Thursday, hitting $1.50. The stock had a trading volume of 369,883 shares, compared to its average volume of 253,544. ArQule has a 52-week low of $0.92 and a 52-week high of $1.68. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 2.33.

ArQule (NASDAQ:ARQL) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.02. During the same period in the prior year, the firm earned ($0.08) EPS. analysts anticipate that ArQule will post -0.39 EPS for the current year.

Several institutional investors have recently bought and sold shares of the company. Point72 Asset Management L.P. purchased a new stake in shares of ArQule during the third quarter worth about $2,220,000. First Eagle Investment Management LLC boosted its holdings in shares of ArQule by 5.0% during the third quarter. First Eagle Investment Management LLC now owns 12,438,996 shares of the biotechnology company’s stock worth $13,807,000 after purchasing an additional 591,421 shares during the period. Curbstone Financial Management Corp boosted its holdings in shares of ArQule by 100.0% during the third quarter. Curbstone Financial Management Corp now owns 104,572 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 52,286 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of ArQule by 0.9% during the second quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 1,385 shares during the period. Institutional investors own 52.12% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “ArQule (ARQL) Upgraded to “Buy” at Needham & Company LLC” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/16/arqule-arql-rating-increased-to-buy-at-needham-company-llc.html.

About ArQule

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Receive News & Stock Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related stocks with our FREE daily email newsletter.